MedTrace Logo

CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)

NCT02316171 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-07-27

Study results available
· View outcomes & findings →

Summary

The study consisted of 2 sequential parts. Part A assessed the safety and tolerability of CAVATAK administered via intravesical instillation in patients with non-muscle invasive bladder cancer scheduled to undergo TUR. Part B assessed the safety and tolerability of CAVATAK administered in sequential combination with low dose Mitomycin C in the same patient population.

Conditions

Interventions

BIOLOGICAL

CVA21

CAVATAK is a purified preparation of CVA21

DRUG

Mitomycin C

Chemotherapy

Sponsors & Collaborators

  • Viralytics

    lead INDUSTRY

Principal Investigators

  • Hardev Pandha · Royal Surrey County Hospital NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-16
Primary Completion
2016-03-14
Completion
2016-03-14

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02316171 on ClinicalTrials.gov